I migliori Astellas podcast (2024)

1
Gene and cell therapies will propel innovation, says Astellas CCO 27:16

10d ago27:16

27:16

Gene and cell therapies will drive innovation for the next 10 years, Claus Zieler, the chief commercial officer at Astellas Pharma Inc., said in this episode of the BioWorld Insider podcast. Developers are on the cusp of breakthroughs because a gene can now be replaced “and that means we can potentially cure a disease rather than intervening in a d…

1
Achieving Health Equity Through All-Payer Models with Dr. Trudy Hall 49:21

3d ago49:21

49:21

🎙 ABOUT DR. TRUDY HALL Dr. Trudy R. Hall has been the Vice President of Medical Affairs and Chief Medical Officer at TidalHealth since July 2022. She previously served in leadership roles at the University of Maryland's Capital Region Health and other UM health centers, overseeing major facilities, including a 345-bed COVID care site during the pan…

1
S08 E03: World Mental Health Day with Boehringer Ingelheim’s Nedim Pipic 24:24

6d ago24:24

24:24

In this episode, Isabel is joined by Nedim Pipic, Senior Vice President and Global Therapeutic Area Head for Mental Health, Boehringer Ingelheim, to mark World Mental Health Day on 10 October 2024. Their conversation dives into the unique challenges faced by those living with serious mental illnesses, the impact of media representation and the role…

1
Gilead inks deal with generics manufacturers to expand HIV drug access, J&J announces layoffs, Amgen sued for hiding $10.7B tax bill [The good, the bad, the ugly] 4:00

7d ago4:00

4:00

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — Gilead inks deal with generics manufacturers to expand HIV drug access The bad — J&J announces layoffs at New Brunswick headquarters The ugly — Amgen sued for hiding $10.7B tax bill…

1
Ep. 69 - Lee Fleisher: An Insider’s Account of CMS’s Alzheimer’s Coverage Decisions 34:36

11d ago34:36

34:36

CMS’s controversial decision to restrict access to Alzheimer’s mAb treatments, including Aduhelm, approved under FDA’s accelerated pathway was a unique case that is unlikely to set a precedent, former CMS CMO Lee Fleisher told BioCentury. “I do not think this will be repeated,” he said. In an interview with The BioCentury Show's Steve Usdin, Fleish…

1
S08 E02: ViiV Healthcare’s Jean-Bernard Simeon on ending the HIV epidemic 27:41

12d ago27:41

27:41

This week, Jean-Bernard Simeon, Senior Vice President and Head, ViiV Healthcare Europe, sits down with the EMJ GOLD team to share his thoughts on the current landscape for patients with HIV in Europe. Together, JB and Jade explore the UNAIDS roadmap to end the HIV epidemic by 2030, the barriers faced by people living with HIV in Europe, stigmas sti…

1
FDA approves BMS schizophrenia drug, bluebird bio announces layoffs, J&J talc subsidiary files for bankruptcy [The good, the bad, the ugly] 3:37

14d ago3:37

3:37

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good —FDA approves BMS schizophrenia drug The bad — bluebird bio announces layoffs The ugly —J&J talc subsidiary files for bankruptcyDi Pharma Manufacturing

1
[Extended Release] Schizophrenia treatment barriers, KarXT, and the future of neuroscience 17:28

18d ago17:28

17:28

Join senior editor Andrea Corona and Sam Clark, CEO and founder of Terran Biosciences, for a discussion on KarXT's landmark approval, schizophrenia treatment barriers, prodrugs, and more. Extended Release is an Off Script series that allows us to revisit conversations with our sources to explore new developments, gain deeper insights, and provide u…

1
Capricor’s CEO pursues a BLA and talks rare disease 15:49

19d ago15:49

15:49

Capricor Therapeutics Inc. just wrapped up a visit with the U.S. FDA and is prepping to file a BLA in October for its Duchenne muscular dystrophy treatment. Linda Marbán, Capricor’s CEO, is the guest on the newest BioWorld Insider podcast and she talks about deramiocel (CAP-1002), the company’s allogeneic cardiac-derived cell therapy, for treating …

1
S08 E01: Moderna’s Chantal Friebertshäuser on improving vaccine confidence 25:48

20d ago25:48

25:48

The EMJ GOLD podcast is back! In the first episode of season 8, Jade sits down with Chantal Friebertshäuser, Senior Vice President and General Manager, EMEAC, Moderna, to discuss how Europe can combat the recent erosion of trust in vaccines. Together, the two explore the role of governments in addressing vaccine hesitancy, improving vaccine educati…

1
Novo Nordisk shares phase 2a obesity trial data, Achilles Therapeutics ends TIL-based therapy, Express Scripts sues FTC [The good, the bad, the ugly] 3:24

21d ago3:24

3:24

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — Novo Nordisk shares phase 2a trial data for obesity treatment The bad — Achilles Therapeutics to discontinue TIL-based therapy The ugly — Express Scripts files lawsuit against FTC…

1
Ep. 68 - Inside BeiGene: CEO John Oyler on Owning the Drug Development Process 35:08

25d ago35:08

35:08

Few CEOs have built a $20 billion biotech in under 15 years, as John Oyler has with BeiGene, managing to stay in that market cap band even through the downmarket. His strategy, to own clinical trials and manufacturing early on, looks particularly prescient in light of the cost and supply constraints threatening many biotechs today. On this episode …

1
[Solutions Spotlight] Optimizing contamination control in pharma facilities 12:32

25d ago12:32

12:32

Drugmakers face stringent regulations to ensure that products remain free from contaminants that could compromise safety and efficacy. Effective contamination control requires meticulous monitoring of environmental conditions, rigorous testing of products, and implementation of robust cleaning and sterilization procedures. To better understand thes…

1
Repairing Fragmented Care with Value-Based Strategies with Dr. Kamal Golla 46:51

24d ago46:51

46:51

🎙 ABOUT DR VISHNUKAMAL GOLLA Dr. Vishnukamal Golla is the medical director for value transformation at Evolent, a specialty and primary care management company. In this role, Dr. Golla leads the implementation of innovative value-based care models in specialty care. In helping Evolent manage approximately $1 billion of risk-based oncology and cardi…

1
Roche wins FDA approval for subcutaneous cancer immunotherapy, Moderna to cut $1.1B in R&D expenses, Teva settles $80M opioid case with Baltimore [The good, the bad, the ugly] 3:34

28d ago3:34

3:34

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — Roche snags FDA nod for subcutaneous cancer immunotherapy The bad — Moderna to cut R&D expenses by $1.1B The ugly — Teva reaches $80M opioid settlement with Baltimore…

1
Season 7 highlights: GOLD Medal Moments 11:55

1M ago11:55

11:55

The new season of the podcast is only a week away, so before we get started – why not have a listen to some of the best bits from Series 7? From a deep dive into women’s health to why the industry thrives on a little healthy competition, there’s plenty to discover in last season’s highlights. As well as the EMJ GOLD team’s analysis of the key theme…

1
Pfizer, Valneva share phase 2 Lyme vax data, IN8bio axes workforce, AstraZeneca employees detained in China [The good, the bad, the ugly] 4:12

1M ago4:12

4:12

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — Pfizer, Valneva share phase 2 positive Lyme vax data The bad — IN8bio axes workforce, halts trial The ugly — AstraZeneca employees detained in ChinaDi Pharma Manufacturing

1
Ep 67 - AAM's Craig Burton on Opportunities, Challenges of U.S. Biosimilars Market 28:51

1M ago28:51

28:51

There is good news in this year’s Association for Accessible Medicines report on savings from biosimilars, including a 30% increase over the last year in savings attributed to biosimilars. The report also explores the economic, policy and regulatory headwinds that are preventing the industry from generating savings at a level that would have a dram…

1
FDA approves Illumina cancer biomarker test, BioMarin reveals more layoffs, FDA hits API maker Global Calcium with 483 [The good, the bad, the ugly] 3:30

1M ago3:30

3:30

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — FDA approves Illumina cancer biomarker test The bad — BioMarin reveals more layoffs The ugly — FDA hits API maker Global Calcium with 483Di Pharma Manufacturing

1
Pharma’s new age of longevity 4:15

2M ago4:15

4:15

The concept of healthspan has recently gained new attention in the pharma industry and rightfully so, given the surprisingly large chasm in the U.S. between average years lived (77.5) and average years lived in good health (63.9). Facing a growing demographic of unhealthy seniors, a handful of innovative biotechs are reframing the longevity discuss…

1
Emergent donates 50k doses of mpox vaccine to Africa, FDA rejects Regeneron blood cancer bispecific antibody, China indicts Astellas exec for espionage [The good, the bad, the ugly] 3:41

2M ago3:41

3:41

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — Emergent donates 50,000 doses of mpox vaccine to Africa The bad — FDA rejects Regeneron blood cancer bispecific antibody The ugly — China indicts Astellas exec for espionage…

1
Popular Episode - Bob Nelsen on AI, China and the IRA 35:33

2M ago35:33

35:33

This is a previously recorded episode of The BioCentury Show from February 22, 2024. Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com to access and watch all prior episodes. In a wide-ranging conversation with BioCentury, Bob Nelsen, co-founder and managing director of Arch Venture Partners, said he is excited…

1
FDA approves Ascendis drug, Lykos PTSD treatment rejected, Novartis bid blocked [The good, the bad, the ugly] 3:21

2M ago3:21

3:21

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — FDA approves Ascendis hypoparathyroidism drug The bad — FDA rejects Lykos MDMA PTSD drug The ugly — Judge blocks Novartis bid to stop generic blockbuster heart drug…

1
Advancing Medicine With Placenta-Derived Cells with Dr. Robert Hariri 1:00:35

2M ago1:00:35

1:00:35

🎙ABOUT DR. ROBERT HARIRI: Dr. Bob Hariri is a pioneering surgeon, biomedical scientist, and serial entrepreneur with expertise in biomedicine and aerospace. He is the founder, chairperson, and CEO of Celularity, Inc., a leader in human cellular therapeutics, and previously founded Anthrogenesis Corporation, which was acquired by Celgene, where he s…

1
S07 E10: Astellas’ Tadaaki Taniguchi on how to challenge the status quo 28:43

2M ago28:43

28:43

In this season finale of the EMJ GOLD podcast, Isabel speaks to Dr Tadaaki Taniguchi, Chief Medical Officer, Head of Medical and Development, Astellas Pharma, about how he strives to challenge the status quo in the pharmaceutical industry. The two discuss how Tadaaki’s time as a surgical oncologist has influenced his leadership style, how collabora…

1
Amneal's Parkinson's pill approved, Novo Nordisk withdraws Wegovy approval expansion bid, FDA delays BeiGene Tevimbra decision [The good, the bad, the ugly] 2:59

2M ago2:59

2:59

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — Amneal gets FDA nod for Parkinson’s pill The bad — Novo Nordisk withdraws bid for Wegovy label expansion in heart failure The ugly — FDA delays decision on BeiGene Tevimbra as a first-line therapy…

1
Ep. 66 - Jane Grogan on Building Biogen’s Growth Engine 32:23

2M ago32:23

32:23

As Jane Grogan anticipates the unmet needs in patients five years from now, she’s harnessing a wave of interest in targeting B cells as a key driver of an immunology expansion at Biogen. In conversation with Editor in Chief Simone Fishburn on The BioCentury Show, Grogan, who became EVP and head of research of Biogen in October, discusses how she’s …

1
Driving Better Outcomes with Ambulatory Surgical Centers 54:26

2M ago54:26

54:26

ABOUT ARIC BURKE Aric brings over eighteen years of experience in ASC consulting, development, and operations. He oversees the strategic vision, operational management, and organizational structure of Atlas, driving its profitability and strategic direction. Before founding Atlas, Aric was the West Market President for United Surgical Partners Inte…

1
S07 E09: Taking control of customer experience 10:55

2M ago10:55

10:55

In this penultimate episode of Season 7, Isabel and Jade sit down to discuss EMJ GOLD’s most recent features of the month – our infographic on optimising pharma’s customer experience journey and an article on how exactly to design this experience. Within the episode, the team explore how the industry may be missing out on insights gathered from HCP…

1
FDA approves Adaptimmune therapy, halts vTv diabetes program; Sanofi sues Sarepta over Duchenne patents [The good, the bad, the ugly] 3:58

2M ago3:58

3:58

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — FDA approves Adaptimmune engineered cell therapy The bad — FDA puts clinical hold on vTv Therapeutics diabetes program The ugly — Sanofi sues Sarepta over manufacturing patents for Duchenne gene ther…

1
S07 E08: ViiV Healthcare’s Harmony Garges on giving voice to people with HIV 15:32

3M ago15:32

15:32

In this week’s edition of the podcast, Isabel and Jade share an interview with Dr Harmony Garges, Chief Medical Officer, ViiV Healthcare. She speaks with Dr Jonathan Sackier, Host, EMJ Podcast, who joined us in Reuters Barcelona where we meet our guest. Together, the two discuss Harmony’s decision to join the pharmaceutical industry, how treating c…

1
FDA approves Sun Pharma hair loss drug, FDA issues warning letter to Brassica, EMA rejects Eisai-Biogen Alzheimer's drug [The good, the bad, the ugly] 3:46

3M ago3:46

3:46

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — FDA approves Sun Pharma hair loss drug The bad — FDA issues harsh warning letter to Indian CDMO Brassica The ugly — EMA issues negative opinion on Eisai-Biogen Alzheimer's drug…

1
The first half of 2024 was strong as M&As and financings dominate 18:00

3M ago18:00

18:00

Karen Carey, BioWorld managing editor and chief analyst, takes a look at the numbers from the first half of 2024. She finds the first six months to be healthy for the biopharma market while the rest of the year is populated with question marks that include the U.S. presidential election and potential interest rate cuts. Download transcript…

1
Ep. 65 - Astellas' Claus Zieler: Global Launches with Local Impact 32:27

3M ago32:27

32:27

As Astellas prepares to launch four products in parallel, Chief Commercial Officer Claus Zieler is balancing the complexity of this multi-faceted enterprise with a simple guiding principle: it has to work at a local level, and that will change with geography, circumstance and time. In conversation with Editor in Chief Simone Fishburn on The BioCent…

1
S07 E07: Kyowa Kirin’s Danie du Plessis on the potential of patient partnerships 29:35

3M ago29:35

29:35

In this week’s episode, Danie du Plessis, Executive Vice President, Pharmaceutical Operations, Kyowa Kirin, sits down with the EMJ GOLD team to share the value that patient partnerships can hold in the industry. Danie explores how patient partnerships have evolved over the years, what companies should be doing to get them to their best potential, t…

1
Genentech's oral weight loss drug shows promise; FDA denies accelerated approval for Agenus' cancer drug; Orexo's opioid overdose drug rejected again [The good, the bad, the ugly] 3:35

3M ago3:35

3:35

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — Genentech's oral weight loss drug shows promise The bad — FDA denies accelerated approval for Agenus' cancer drug The ugly — Orexo's opioid overdose drug rejected again…

1
The cost of delays in development and sales: It’s probably not what you think 16:43

3M ago16:43

16:43

Two costs of developing drug candidates have been upended by new research from the Tufts University School of Medicine’s Center for the Study of Drug Development. New data have produced some very different numbers than you might expect in the cost of a single day of a clinical trial and of missing a day to generate prescription drugs sales. The cen…

1
S07 E06: AZ’s Stefan Woxström on why without health, we don’t have anything 40:41

3M ago40:41

40:41

Tune in to the latest episode of the EMJ GOLD podcast as Isabel and Jade cross the halfway point of the season with special guest host Dr Jonathan Sackier of the EMJ podcast. In this episode, the team listen back to Jonathan's discussion with Stefan Woxström, Senior Vice President Europe and Canada, AstraZeneca at Reuters Events: Pharma 2024 in Bar…

1
Pfizer advances obesity pill, FDA rejects Novo insulin, FTC releases PBM report [The good, the bad, the ugly] 3:28

3M ago3:28

3:28

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — Pfizer advances once-daily obesity pill The bad — FDA rejects Novo Nordisk once-weekly insulin The ugly — FTC releases long-awaited report on PBMsDi Pharma Manufacturing

1
Ep. 64 - NPC CEO John O’Brien: Why America Needs an Honest Conversation About Drug Pricing 33:36

3M ago33:36

33:36

Ignorance about the path from scientific discovery to approved drugs, high out-of-pocket costs, and a byzantine healthcare system that obscures net prices while inflating list prices have fueled policies that threaten biomedical progress, John O’Brien, CEO of think tank National Pharmaceutical Council, told BioCentury. In an interview with The BioC…

1
S07 E05: Sandoz’s Claire D’Abreu-Hayling on leading with love 19:54

3M ago19:54

19:54

This week, Claire D'Abreu-Hayling, Chief Scientific Officer, Sandoz, joins Isabel on the podcast to share how leading with love rather than ruling with an iron fist is the best way to get results in the pharmaceutical industry. In this episode, Claire and Isabel discuss how she fell in love with science as a child, the leadership skills she has gai…

1
Lilly Alzheimer’s drug gets full approval, Rocket gene therapy rejected, Eisai, BMS end ADC partnership [The good, the bad, the ugly] 3:44

3M ago3:44

3:44

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — FDA grants Eli Lilly Alzheimer’s drug full approval The bad — FDA rejects Rocket gene therapy The ugly — Eisai, BMS end ADC partnershipDi Pharma Manufacturing

1
[Solutions Spotlight] Streamlining oral dose packaging design 31:57

3M ago31:57

31:57

By integrating a Quality by Design (QbD) approach, developers can design robust packaging from the outset, drastically reducing development time and costs. Understanding how moisture affects a product is key, allowing developers to use industry-accepted and validated models to predict and address potential stability issues early in the design phase…

1
S07 E04: How creativity and innovation are revolutionising medical education 11:10

3M ago11:10

11:10

Join EMJ GOLD for a special edition of the podcast, in which Isabel is joined by Tim Uden, Creative Director, EMJ to discuss the new frontier of medical education tools and skills. In this episode, the two explore how new technological offerings, such as interactive articles, are transforming the space for medical content – enabling content creator…

1
Verona wins COPD nod, FDA rejects Merck-Daiichi ADC, Glenmark recalls potassium chloride capsules [The good, the bad, the ugly] 3:42

4M ago3:42

3:42

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — Verona wins FDA nod for COPD The bad — FDA issues CRL to Merck-Daiichi lung cancer ADC The ugly — Glenmark recalls 114 batches of potassium chloride capsules…

1
Ep. 63 - Day One's Jeremy Bender: Building Pediatric Oncology from the Ground Up 32:27

4M ago32:27

32:27

Pediatric cancer drug development is difficult: it requires high levels of safety, involves parents as well as the patients, and has small populations that can make it difficult to achieve the revenues that reward the investment. Squaring that circle, according to Day One Biopharmaceuticals CEO Jeremy Bender, is not impossible, but takes a dedicate…

1
Pride Special: J&J's Edmond Chan on the value in being your authentic self 18:18

4M ago18:18

18:18

As we approach the end of Pride month, Jade explores how the pharmaceutical industry can best support staff and patients who identify as part of the LGBTQ+ community. She talks with Edmond Chan, Senior Director, EMEA Therapeutic Area Lead, Haemato-Oncology, J&J, who shares his personal views on how the industry can improve health outcomes and encou…

1
Gilead HIV shot delivers zero infections, Takeda epilepsy drug misses endpoints, Lilly goes after counterfeiters [The good, the bad, the ugly] 3:36

4M ago3:36

3:36

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — Gilead twice-yearly HIV shot delivers zero infections in trial The bad — Takeda epilepsy drug misses endpoints in trials The ugly — Eli Lilly goes after counterfeiters…

1
Working with IDNs: The Pharma Perspective 1:12:50

4M ago1:12:50

1:12:50

ABOUT HEALTH CARE ROUNDS Health Care Rounds is a weekly podcast developed for health care leaders who are at the forefront of health care delivery and payment reform. Join Darwin Research Group founder and CEO John Marchica as he discusses the latest advancements in health care business news and policy developments. ABOUT MATT PORTCH Matt Portch is…

1
FDA backs Lilly Alzheimer’s drug; Pfizer Duchenne gene therapy fails; Talc plaintiffs seek J&J bankruptcy restraining order [The good, the bad, the ugly] 4:25

4M ago4:25

4:25

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — FDA AdComm backs Eli Lilly Alzheimer’s drug The bad — Pfizer gene therapy fails phase 3 Duchenne trial The ugly — Talc plaintiffs seek restraining order on J&J bankruptcy tactic…

Podcast che vale la pena ascoltare

Podcast di Astellas

Podcast che vale la pena ascoltare

Guida rapida